Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure

View through CrossRef
ABSTRACTBackground and AimsThe impact of portal hypertension (PH) during acute‐on‐chronic liver failure (ACLF) remains unclear. This study investigated the link between underlying PH severity, systemic inflammation (SI), and the course of ACLF.MethodsConsecutive patients with ACLF (n = 192) who met the EASL‐CLIF criteria were retrospectively included. PH severity (hepatic venous pressure gradient, HVPG; platelet count, PLT; and other clinical/radiologic PH surrogates) and SI (white blood cell count; C‐reactive protein [CRP], interleukin‐6) were assessed at the last pre‐ACLF visit, ACLF diagnosis (D0), and after 7 (D7), 28 (D28), and 90 (D90) days.ResultsAll patients had clinical/radiological signs of PH, and 91 (47%) patients developed ACLF grade 1, 62 (32%) ACLF‐2, and 39 (21%) ACLF‐3. Patients with different D0‐ACLF grades showed similar SI biomarker levels pre‐ACLF, whereas these increased significantly during ACLF. Median PLT decreased in parallel with the ACLF grade and from D0 (ACLF‐3:72; vs. ACLF‐2:81; vs. ACLF‐1:91 G/L; p = 0.094) to D7 (ACLF‐3:39 vs. ACLF‐2:64; vs. ACLF‐1:89 G/L; p < 0.001). In multivariable Cox regression models, D0‐PLT (aHR: 0.96 per 10 G/L [95% CI: 0.93–0.99], p = 0.015) independently predicted D28 mortality. A logistic regression model including sex, D0‐PLT, D0‐CRP, and CLIF‐C ACLF score predicted D28 mortality (AUROC: 0.79 [0.73–0.86]; p < 0.001) and outperformed (p = 0.036) the MELD‐Na score (AUROC: 0.71 [0.63–0.78]; p < 0.001).ConclusionsAlthough PH is a necessary condition for ACLF development, underlying PH severity does not confer a risk for higher ACLF severity but impacts survival after ACLF resolution. PLT emerged as a predictor of D28 mortality, independent of the CLIF‐C ACLF score.
Title: Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure
Description:
ABSTRACTBackground and AimsThe impact of portal hypertension (PH) during acute‐on‐chronic liver failure (ACLF) remains unclear.
This study investigated the link between underlying PH severity, systemic inflammation (SI), and the course of ACLF.
MethodsConsecutive patients with ACLF (n = 192) who met the EASL‐CLIF criteria were retrospectively included.
PH severity (hepatic venous pressure gradient, HVPG; platelet count, PLT; and other clinical/radiologic PH surrogates) and SI (white blood cell count; C‐reactive protein [CRP], interleukin‐6) were assessed at the last pre‐ACLF visit, ACLF diagnosis (D0), and after 7 (D7), 28 (D28), and 90 (D90) days.
ResultsAll patients had clinical/radiological signs of PH, and 91 (47%) patients developed ACLF grade 1, 62 (32%) ACLF‐2, and 39 (21%) ACLF‐3.
Patients with different D0‐ACLF grades showed similar SI biomarker levels pre‐ACLF, whereas these increased significantly during ACLF.
Median PLT decreased in parallel with the ACLF grade and from D0 (ACLF‐3:72; vs.
ACLF‐2:81; vs.
ACLF‐1:91 G/L; p = 0.
094) to D7 (ACLF‐3:39 vs.
ACLF‐2:64; vs.
ACLF‐1:89 G/L; p < 0.
001).
In multivariable Cox regression models, D0‐PLT (aHR: 0.
96 per 10 G/L [95% CI: 0.
93–0.
99], p = 0.
015) independently predicted D28 mortality.
A logistic regression model including sex, D0‐PLT, D0‐CRP, and CLIF‐C ACLF score predicted D28 mortality (AUROC: 0.
79 [0.
73–0.
86]; p < 0.
001) and outperformed (p = 0.
036) the MELD‐Na score (AUROC: 0.
71 [0.
63–0.
78]; p < 0.
001).
ConclusionsAlthough PH is a necessary condition for ACLF development, underlying PH severity does not confer a risk for higher ACLF severity but impacts survival after ACLF resolution.
PLT emerged as a predictor of D28 mortality, independent of the CLIF‐C ACLF score.

Related Results

[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
EVALUATION AND COMPARISON OF LIVER MARKERS IN ACUTE LIVER FAILURE VS CHRONIC LIVER FAILURE IN DISTRICT FAISALABAD: A CROSS-SECTIONAL STUDY
EVALUATION AND COMPARISON OF LIVER MARKERS IN ACUTE LIVER FAILURE VS CHRONIC LIVER FAILURE IN DISTRICT FAISALABAD: A CROSS-SECTIONAL STUDY
Background: Liver failure is a life-threatening clinical condition resulting from the inability of the liver to maintain its metabolic, synthetic, and detoxification functions. Acu...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
GW24-e3137 The etiology investigate of hypertension incidence in children
GW24-e3137 The etiology investigate of hypertension incidence in children
Objectives Through retrospective analysis of related factors of children’s hypertension what is composed by primary hypertension and secondary hypertension diseas...
Risk factors and severity of acute liver injury in non-chronic liver disease and chronic liver disease patients
Risk factors and severity of acute liver injury in non-chronic liver disease and chronic liver disease patients
Objectives To study factors related to acute liver injury and compare the severity and risk of those factors in patients with and without chronic liver disease. Methods This cross...

Back to Top